Rare eye cancer yields to targeted drug

The novel kinase inhibitor selumetinib may be the first treatment to shrink advanced uveal melanoma, based on phase II trial results. Fully 15% of patients had at least a 30% reduction in tumor volume on the novel drug compared with none on temozolomide, the researchers reported at the American Society of Clinical Oncology meeting. Read more here.